Details of Disease

General Information of Disease (ID: DISS93V5)

• Disease Name: Oral mucositis
• Synonyms: oral mucositis; mouth mucosa inflammation; mucositis oral; inflammation of mouth mucosa
• Disease Class: DA01: Oral mucositis
• Definition: Inflammation of the oral mucosa due to local or systemic factors.
• Disease Hierarchy:
  DISWD40R: Disease
  DIS3FXDI: Mucositis
  DISBUPH5: Mouth mucosa disorder
  DISS93V5: Oral mucositis
• ICD Code:
  ICD-11: ICD-11: DA01.11
  ICD-10: ICD-10: K12.3
  ICD-9: ICD-9: 528
  Expand ICD-11: 'DA01.11
  Expand ICD-10: 'K12.3
  Expand ICD-9: 528
• Disease Identifiers:
  MONDO ID: MONDO_0004842
  MESH ID: D013280
  UMLS CUI: C0038362
  MedGen ID: 52511
  HPO ID: HP:0010280
  SNOMED CT ID: 61170000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Palifermin	DM9JOYP	Approved	NA	[1]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dusquetide	DMKU3R1	Phase 3	Peptide	[2]
AG-013	DMGC970	Phase 2/3	NA	[3]
GC4419	DM4KLCS	Phase 2	NA	[4]
PMX-30063	DMYBWEB	Phase 2	NA	[5]
Lactermin	DM8ANIM	Phase 1	NA	[6]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
E6014	DMBDIKM	Discontinued in Phase 3	NA	[7]
Repifermin	DMSOALX	Discontinued in Phase 2	NA	[8]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Hebervis	DMZ4A0R	Investigative	NA	[9]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 6 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
IFNA2	TTSIUJ9	Limited	Biomarker	[10]
APEH	TTYWEDQ	Strong	Genetic Variation	[11]
CSF3	TT5TQ2W	Strong	Biomarker	[12]
DPYD	TTZPS91	Strong	Genetic Variation	[13]
FBXO3	TTUX14L	Strong	Genetic Variation	[14]
FGF7	TTFY134	Strong	Biomarker	[15]

This Disease Is Related to 7 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CDAN1	OTCVZRG6	Limited	Biomarker	[16]
GRHL3	OT1V4ZEH	Strong	Biomarker	[17]
NBN	OT73B5MD	Strong	Genetic Variation	[18]
DMRTA1	OTRZY9E9	Definitive	Biomarker	[19]
NARS1	OTFS4J1W	Definitive	Biomarker	[20]
SERP1	OT60XXUP	Definitive	Biomarker	[21]
SPNS1	OTSJ3BJ2	Definitive	Biomarker	[20]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6954).
• [2] ClinicalTrials.gov (NCT03237325) DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer. U.S. National Institutes of Health.
• [3] AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 2010 Jul;46(7):564-70.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT01211470) Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus. U.S. National Institutes of Health.
• [6] Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets. 2007 Mar;7(2):157-67.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018355)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009979)
• [9] Leadership in BioBusiness. Dr Gurinder S Shahi. Page(36).
• [10] All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma.Haematologica. 1997 May-Jun;82(3):354-6.
• [11] Polymorphism of regulatory region of APEH gene (c.-521G>C, rs4855883) as a relevant predictive factor for radiotherapy induced oral mucositis and overall survival in head neck cancer patients.Oncotarget. 2018 Jul 3;9(51):29644-29653. doi: 10.18632/oncotarget.25662. eCollection 2018 Jul 3.
• [12] The effects of recombinant human granulocyte colony-stimulating factor mouthwash on radiotherapy-induced oral mucositis in locally advanced nasopharyngeal carcinoma patients.Adv Clin Exp Med. 2017 May-Jun;26(3):409-413. doi: 10.17219/acem/61913.
• [13] Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.Eur J Cancer. 2018 Oct;102:31-39. doi: 10.1016/j.ejca.2018.07.009. Epub 2018 Aug 13.
• [14] Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study.Bone Marrow Transplant. 2019 Jun;54(6):894-902. doi: 10.1038/s41409-018-0356-5. Epub 2018 Oct 19.
• [15] In silico analysis of different signal peptides for the secretory production of recombinant human keratinocyte growth factor in Escherichia coli.Comput Biol Chem. 2019 Jun;80:225-233. doi: 10.1016/j.compbiolchem.2019.03.003. Epub 2019 Mar 29.
• [16] Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.Invest New Drugs. 2019 Feb;37(1):109-117. doi: 10.1007/s10637-018-0634-5. Epub 2018 Jul 11.
• [17] Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer.Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):320-328. doi: 10.1016/j.ijrobp.2019.10.023. Epub 2019 Oct 25.
• [18] Polymorphisms in radio-responsive genes and its association with acute toxicity among head and neck cancer patients.PLoS One. 2014 Mar 4;9(3):e89079. doi: 10.1371/journal.pone.0089079. eCollection 2014.
• [19] GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis.Support Care Cancer. 2015 Mar;23(3):841-9. doi: 10.1007/s00520-014-2406-x. Epub 2014 Sep 14.
• [20] Low-level laser therapy dosimetry most used for oral mucositis due to radiotherapy for head and neck cancer: a systematic review and meta-analysis.Crit Rev Oncol Hematol. 2019 Jun;138:14-23. doi: 10.1016/j.critrevonc.2019.03.009. Epub 2019 Mar 31.
• [21] Genomic features of a multidrug-resistant Enterobacter cloacae ST279 producing CTX-M-15 and AAC(6')-Ib-cr isolated from fatal infectious stomatitis in a crossed pit viper (Bothrops alternatus).J Glob Antimicrob Resist. 2018 Dec;15:290-291. doi: 10.1016/j.jgar.2018.11.009. Epub 2018 Nov 15.